Brand-Generic/MOA & Drugs Flashcards
Novastan
- MOA
- Indication
- Form
Argatroban
- Direct thrombin inhibitor
- HIT
- F: IV
Angiomax
- MOA
- Form:
Bivalirudin
- Direct thrombin inhibitor
- F: IV
Iprivask
- MOA:
- Form:
- Indication
- CrCl adjustment
Desirudin
- MOA: Direct thrombin inhibitor (DTI)
- 15mg SQ Q12H
- I: DVT ppx
- CrCl
Pradaxa
- MOA
- Dose
CrCl > 30
CrCl 15-30
CrCl
Dabigatran
- MOA: Direct thrombin inhibitor (DTI
- Dose: 150 mg BID
- CrCl 15-30: 75mg BID
- CrCl
Fragmin
- MOA:
- D/Route/Frequency
Dalteparin
- MOA: LMWH => FXa Inhibitors
- 2500-5000 units SC QD
Innohep
- MOA:
- Route/Frequency
Tinzaprin
- MOA: LMWH => FXa Inhibitors
- SC QD
Lovenox
- MOA:
- Route
Enoxaparin
- MOA: LMWH => FXa Inhibitors
- SC
Xarelto
- MOA:
- Indication
- Dose
- Administration instruction
Rivaroxaban
- MOA: FXa Inhibitors Indication - Prevention of stroke in a.fib - DVT pxx in HIP/Knee replacement - DVT or PE treatment Dose - PE/DVT tx: 15mg BID x 3wk then 20mg QD - Take w/ food for dose 20mg
Arixtra
- MOA:
- Indication
Fondaparinux
- MOA: FXa Inhibitors
Indication - DVT pxx in HIP/Knee replacement
- DVT or PE treatment
Coumadin
Warfarin
Eliquis
- Indication:
- Dose:
- Surgery/Antidote:
Apixaban
Indication
- Prevention of stroke in a.fib
- DVT pxx in HIP/Knee replacement
- DVT or PE treatment
- D: 5mg PO BID
- 2.5 mg PO BID in pts w/ 2 of the followings: age >/= 80 y, BW /= 1.5 mg/dL, on strong inhibitor of 3A4 & P-gp (keto/itratroconazole, ritonavir)
- Surgery: d/c 48H prior of mod/high risk surgery; d/c 24H prior to low risk surgery
- Antidote: no
Savaysa
- Indication
Edoxaban
Indication
- Prevention of stroke in a.fib
- DVT pxx in HIP/Knee replacement
- DVT or PE treatment
ReoPro
- MOA:
Abciximab
- MOA: block fibrinogen bind to GPIIb/IIIa receptor on platelet = prevents platelets from aggregrating together
Aggrastat
- MOA:
Tirofiban
- MOA: block fibrinogen bind to GPIIb/IIIa receptor on platelet = prevents platelets from aggregrating together
Integrilin
- MOA:
Eptifibatide
- MOA: block fibrinogen bind to GPIIb/IIIa receptor on platelet = prevents platelets from aggregrating together
Pletal
- MOA:
- Indication
Cilostazole
- MOA: ADP receptor antagonist (thienopyridines)
- I: Claudication
Ticlid
- MOA:
Ticlopidine
- MOA: ADP receptor antagonist
Plavix
- MOA:
Clopidogrel
- MOA: ADP receptor antagonist
Effient
- MOA:
Prasugrel
- MOA: ADP receptor antagonist
Brilinta
- MOA:
Ticagrelor
- MOA: ADP receptor antagonist
Persantine
- MOA:
Dipyridamole
MOA: Reversible inhibitors of platelet aggregation: inc cAMP in platelets
ASA + Dipyridamole
- Dose
Aggrenox
- Dose: 1 cap BID
Activase
-MOA:
Alteplase (tPA)
-MOA: Thrombolytic agent: Direct activates plasminogen to form plasmin which leads to clot lysis.
Retavase
-MOA:
Reteplase (rPA)
-MOA: Thrombolytic agent: Direct activates plasminogen to form plasmin which leads to clot lysis.
Strepase
-MOA:
Streptokinase (SK)
-MOA: Thrombolytic agent: Direct activates plasminogen to form plasmin which leads to clot lysis.
TNKase
-MOA:
Tenecteplase (TNK-tPA)
-MOA: Thrombolytic agent: Direct activates plasminogen to form plasmin which leads to clot lysis.
Abbokinase
-MOA:
Urokinase
-MOA: Thrombolytic agent: Direct activates plasminogen to form plasmin which leads to clot lysis.
List anticoagulants that is given PO
- Rivaroxaban (Xarelto) - 10 mg QD
- FXa inhibitor - Warfarin (Coumadin) - 2-10 mg QD
- Vit K antagonist. Only 1 requires monitor - Dabigatran (Pradaxa) - 150 mg BID
- Direct thrombin inhibitor => reversible - Apixaban (Eliquis) - 5 mg BID
- Edoxaban (Lexiana)
Zontivity
- MOA
- Indication
Vorapaxar
- MOA: inhibits protease activated receptor-1
- Indications: Prevention of thrombotic events post MI in pt with PAD with ASA or Clopidogrel